Next Quarterly Earnings
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Incyte, a US-based biopharmaceutical company, is dedicated to the discovery, development, and commercialization of innovative therapeutics. With a strong focus on oncology, inflammation, and autoimmune diseases, Incyte aims to improve the lives of patients globally. The company drives medical progress through targeted research and development, striving to provide much-needed treatment solutions.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Incyte is scheduled to report its next quarterly earnings on 11/03/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Incyte last reported quarterly earnings on 7/28/2026 (Q2 2026). Earnings per share (EPS) came in at 3.09 USD.
Across its last 5 earnings reports, Incyte stock moved by ±5.8% on average the following day. The largest reaction was +9.3% on 07/28/2026; 2 of 5 reactions were positive.
Incyte has beaten analyst EPS estimates in 4 of its last 5 evaluated quarters (beat rate: 80%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.